Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional effects of small molecule targeting of ARID1A

ABSTRACT: Transcriptional effects of small molecule targeting of ARID1A

PROVIDER: PRJNA454308 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7084785.fastq.gz	Fastqsanger.gz
	SRR7084786.fastq.gz	Fastqsanger.gz
	SRR7084787.fastq.gz	Fastqsanger.gz
	SRR7084788.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Transcriptional effects of small molecule targeting of ARID1A

Project description:We used RNA-seq to characterize the effects of ARID1A knockout on gene expression in mouse embryonic stem cells (ESCs).

2018-07-27 | GSE113872 | GEO

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Project description:Small-molecule targeting of brachyury transcription factor addiction in chordoma

| PRJNA432043 | ENA

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Project description:Small-molecule targeting of brachyury transcription factor addiction in chordoma

| PRJNA498625 | ENA

Targeting cancer with small molecule panKRAS degraders

Project description:Despite the high prevalence of cancers driven by KRAS mutations, to date only the G12C mutation has been clinically proven to be druggable via covalent targeting of the mutated cysteine amino acid residue. However, in many cancer indications other KRAS mutations, such as G12D and -V, are far more prevalent and small molecule concepts that can address a wider variety of oncogenic KRAS alleles are in high clinical demand. Here we show that a single small molecule degrader can be used to simultaneously and potently target multiple KRAS alleles, including those not yet tractable by inhibitors. Degradation of oncogenic KRAS results in profound and sustained pathway modulation across a broad range of KRAS mutant cell lines. As a result, KRAS degraders inhibit growth of the majority of cancer cell lines driven by KRAS mutations while sparing models without genetic KRAS aberrations. Finally, we demonstrate that pharmacological degradation of oncogenic KRAS leads to tumour regression in vivo. Together, these findings unveil a new path towards addressing KRAS driven cancers with small molecule degraders. This experiment corresponds to Figure 2g

2024-10-01 | PXD045460 | Pride

Targeting cancer with small molecule panKRAS degraders

2024-10-02 | PXD045416 | Pride

A natural small molecule alleviates liver fibrosis by targeting apolipoprotein L2

Project description:A natural small molecule alleviates liver fibrosis by targeting apolipoprotein L2

| PRJNA1052009 | ENA

Small-molecule targeting of brachyury transcription factor addiction in chordoma [rnaseq_compound]

Project description:Small-molecule targeting of brachyury transcription factor addiction in chordoma [rnaseq_compound]

| PRJNA498620 | ENA

Small-molecule targeting of brachyury transcription factor addiction in chordoma [rnaseq_sgrna]

Project description:Small-molecule targeting of brachyury transcription factor addiction in chordoma [rnaseq_sgrna]

| PRJNA498627 | ENA

Targeting cancer with small molecule pan-KRAS degraders

Project description:Despite the high prevalence of cancers driven by KRAS mutations, to date only the G12C mutation has been clinically proven to be druggable via covalent targeting of the mutated cysteine amino acid residue1. However, in many cancer indications other KRAS mutations, such as G12D and -V, are far more prevalent and small molecule concepts that can address a wider variety of oncogenic KRAS alleles are in high clinical demand2. Here we show that a single small molecule can be used to simultaneously and potently degrade 13 out of 17 of the most prevalent oncogenic KRAS alleles, including those not yet tractable by inhibitors. Compared with inhibition, degradation of oncogenic KRAS results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines. As a result, KRAS degraders inhibit growth of the majority of cancer cell lines driven by KRAS mutations while sparing models without genetic KRAS aberrations. Finally, we demonstrate that pharmacological degradation of oncogenic KRAS leads to tumour regression in vivo. Together, these findings unveil a new path towards addressing KRAS driven cancers with small molecule degraders. This is the proteomics analysis of ACBI3 and compoun 8, its negative control.

2024-10-01 | PXD050650 | Pride

Targeting the NFAT:AP-1 transcriptional complex on DNA with a small-molecule inhibitor

Project description:Targeting the NFAT:AP-1 transcriptional complex on DNA with a small-molecule inhibitor

| PRJNA516414 | ENA